TY - JOUR
T1 - Hybrid molecules based on 1,3,5‐triazine as potential therapeutics: A focused review
AU - Prasher, Parteek
AU - Sharma, Mousmee
AU - Aljabali, Alaa A. A.
AU - Gupta, Gaurav
AU - Negi, Poonam
AU - Kapoor, Deepak N.
AU - Singh, Inderbir
AU - Zacconi, Flavia C.
AU - Jesus Andreoli Pinto, Terezinha
AU - Webba Da Silva, Mateus
AU - Bakshi, Hamid A.
AU - Chellappan, Dinesh Kumar
AU - Tambuwala, Murtaza M.
AU - Dua, Kamal
N1 - Funding Information:
P. P. thanks the Department of Chemistry, University of Petroleum & Energy Studies (UPES), M. S. thanks the Department of Chemistry, Uttaranchal University (UU), The authors duly acknowledge Department of Chemistry, Guru Nanak Dev University (GNDU) for providing requisite resources for completing this work. G. G., D. N. K. thank Department of Pharmacy, Shoolini University for resources. D. K. C. thanks IMU, Malaysia for research infrastructure. M. M. T. and K. D. thanks Ulster University and University of Technology Sydney for providing research facilities.
Publisher Copyright:
© 2020 Wiley Periodicals, lnc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/11/10
Y1 - 2020/11/10
N2 - Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.
AB - Majority of the representative drugs customarily interact with multiple targets manifesting unintended side effects. In addition, drug resistance and over expression of the cellular efflux-pumps render certain classes of drugs ineffective. With only a few innovative formulations in development, it is necessary to identify pharmacophores and novel strategies for creating new drugs. The conjugation of dissimilar pharmacophoric moieties to design hybrid molecules with an attractive therapeutic profile is an emerging paradigm in the contemporary drug development regime. The recent decade witnessed the remarkable biological potential of 1,3,5-triazine framework in the development of various chemotherapeutics. The appending of the 1,3,5-triazine nucleus to biologically relevant moieties has delivered exciting results. The present review focuses on 1,3,5-triazine based hybrid molecules in the development of pharmaceuticals.
KW - 1,3,5-triazine
KW - anti-Alzheimer's activity
KW - anti-inflammatory activity
KW - anticancer activity
KW - antimicrobial activity
KW - antiplasmodial activity
KW - hybrids
KW - multidrug-resistance
UR - http://www.scopus.com/inward/record.url?scp=85087217639&partnerID=8YFLogxK
U2 - 10.1002/ddr.21704
DO - 10.1002/ddr.21704
M3 - Review article
C2 - 32579723
VL - 81
SP - 837
EP - 858
JO - Drug Development Research
JF - Drug Development Research
SN - 1098-2299
IS - 7
ER -